Unilever, which also makes Dove soap and PG Tips, will axe the roles in more than 100 countries.
Image source, Reuters
Consumer goods giant Unilever has confirmed it will cut about 1,500 jobs globally as part of an overhaul of its management and structure.
The Marmite-to-Domestos maker said the 5% cut in the workforce would not affect shopfloor jobs in factories.
Unilever is under pressure after a failed £50bn bid for a division of GlaxoSmithKline, and some shareholders have demanded changes.
The firm employs more than 6,000 people in its UK and Ireland operations.
The new Unilever will be re-organised around five divisions, including Beauty, Personal Care and Ice Cream, resulting in several senior executive changes along with cuts further down the management chain.
“Our new organisational model has been developed over the last year and is designed to continue the step-up we are seeing in the performance of our business,” said chief executive Alan Jope.
“Moving to five category-focused Business Groups will enable us to be more responsive to consumer and channel trends, with crystal-clear accountability for delivery. Growth remains our top priority and these changes will underpin our pursuit of this.”
Last week, Unilever sparked anger from some investors when it dropped a short-lived pursuit of GlaxoSmithKline’s (GSK) healthcare business.
Unilever had initially said it wanted a bigger slice of the personal healthcare and hygiene market, to offset slow growth in its foods business.
But GSK, which owns brands such as Sensodyne toothpaste and Panadol painkillers, said the offer “fundamentally undervalued” the division and Unilever has since refused to raise its bid.
The saga has sparked unease about the firm’s management under Mr Jope, with the head of Unilever’s 13th biggest investor labelling the GSK bid as a “near death experience”.
In a scathing attack, Terry Smith, who runs Fundsmith, criticised Unilever’s “meaningless platitudes” over its social and environmental commitments and told Mr Jope to focus on improving the existing businesses “before taking on any more challenges” like the GSK bid.
Unilever, one of the biggest companies on the FTSE 100, is also one of the biggest dividend payers to shareholders and pension funds.
Powerful activist investor Nelson Peltz has also been agitating for change, raising a question mark over Mr Jope’s future.
After the humiliation of having its bids for GSK’s consumer healthcare business repeatedly rejected, this is a real “What next?” moment for Unilever.
The answer appears to be to knuckle down and focus on the existing business, trimming out excess fat and attempting to accelerate growth, rather than building new empires.
It is likely to be a more popular approach with leading investors, several of whom were deeply unhappy with the idea of a move into the personal healthcare business.
The fact that activist investor Nelson Peltz has come on board is likely to add extra urgency to the restructuring process.
But that still leaves question marks hanging over chief executive Alan Jope and his team. Can they restore their lost credibility – and do they have anything else up their sleeves?
Mr Peltz’s hedge fund Trian Partners has previously demanded reforms at rival consumer goods firms Procter & Gamble and Mondelez.
It emerged on Monday that Trian had taken a stake in Unilever. The size of the stake is not known but Mr Peltz’s decision pleased investors, with shares in the company jumping by 7.3% in London on Monday.
In a note, analysts at Barclays said Mr Peltz’s investment “will not be that much of a surprise to industry specialists”.
“From Unilever’s perspective, the status quo is not an option,” they added. “It would seem that the stars are aligning with both Unilever management and an activist pushing for more urgency.”